Compare Global X Data Center & Digital Infra ETF (DTCR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Data Center & Digital Infra ETF vs Repligen Corporation Common Stock — how do they compare? Global X Data Center & Digital Infra ETF trades at $26.12 (market cap $2.11B), while Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 5.4× Global X Data Center & Digital Infra ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Global X Data Center & Digital Infra ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Data Center & Digital Infra ETF for 17 Days and Repligen Corporation Common Stock for 0 Days on average.
| DTCR | RGEN | |
|---|---|---|
Market Cap | $2.11B | $11.31B |
Volume | 781,926 | 1,216,919 |
Sector | Sector/Thematic | Health |
52-Week High | $32.46 | $194.57 |
52-Week Low | $19.73 | $102.87 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DTCR trades at $27.33, down 1.44% on the day, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. Recent news highlights DTCR's position as a key ETF for AI infrastructure exposure, with coverage emphasizing its blend of real estate stability and growth from digital infrastructure sectors. The ETF has gained attention as a picks-and-shovels play in the AI boom.
The outlook for DTCR appears favorable given sustained AI infrastructure investment, though risks include sector volatility and interest rate sensitivity. Analyst sentiment remains positive with buy recommendations citing long-term growth potential from diversified technology and real estate holdings.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Data Center & Digital Infra ETF
Global X Data Center & Digital Infrastructure ETF seeks exposure to companies involved in data centers and digital infrastructure. Its holdings span areas such as digital infrastructure, networking, and related real estate.
Read more on DTCR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
